A clinical review sets out where the evidence for Janus kinase inhibitors in childhood alopecia areata actually stands. Ritlecitinib is the only agent the FDA has approved for the condition in children, and only from age 12. Everything else — abrocitinib, baricitinib, deuruxolitinib, ruxolitinib, tofacitinib and upadacitinib — is used off-label in this age group, and below 12 all of it is.
The reported experience across these agents describes meaningful regrowth with what the authors characterise as generally favourable safety, but the review is explicit that outcome reporting is heterogeneous between studies and reports. That means the regrowth figures quoted for different agents are not comparable with each other, and none of them is a trial result in children under 12.
Two selection signals are worth carrying into clinic. The review suggests JAK inhibitors may be of particular benefit where there is concomitant atopic or autoimmune disease, and possibly where IgE is raised with eosinophilia — a plausible overlap given how often atopic dermatitis and alopecia areata coexist in the same child. It also suggests early-onset and severe disease may warrant considering systemic therapy sooner than has been usual.
In India the practical position is different again: several of these agents are available and comparatively affordable as generics, which makes the prescribing question easier and the consent conversation harder. Off-label systemic immunomodulation in a child, for a condition that is not life-threatening, needs the psychosocial burden documented alongside the alopecia severity — and a monitoring schedule agreed before the first prescription, not after it.
- Name the off-label status explicitly in the consent conversation for any JAK inhibitor in a child under 12
- Document the psychosocial burden as well as the extent of hair loss before starting systemic therapy
- Consider a JAK inhibitor earlier where the child also has atopic or autoimmune disease
- Agree the baseline and follow-up monitoring schedule before the first prescription, not at the first review
- Do not compare regrowth figures between agents — the review states outcome reporting was heterogeneous
Why it matters
The drugs are increasingly available and increasingly asked for, while the evidence base under age 12 is uncontrolled experience.
Don't overread it
This is a narrative clinical review of reported experience, not a trial — the safety characterisation rests on heterogeneous case series.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for dermatology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free